Brief: RhoVac AB Confirms Previous Forecast To Be Able To Conclude Recruitment For Multi-Centre Bravac Phase IIb Study In Quarter 3 2021
31/05/2021 16:02
May 31 (Reuters) - RhoVac AB RHOVAC.TE :
* RHOVAC AB - CONFIRMS PREVIOUS FORECAST TO BE ABLE TO
CONCLUDE
RECRUITMENT FOR MULTI-CENTRE BRAVAC PHASE IIB STUDY IN QUARTER 3
2021
* RHOVAC AB - THERE ARE LESS THAN 50 PATIENTS LEFT TO
RECRUIT IN
BRAVAC PHASE IIB STUDY AND CURRENT RECRUITMENT PACE POINTS TO A
CLOSE IN AUGUST
Source text for Eikon: urn:newsml:reuters.com:*:nPn4PWCzja
Further company coverage: RHOVAC.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chosa Oncology AB
See all newsBrief: Chosa Oncology Appoints Gerton Jönsson As New Chief Financial Officer
Brief: CHOSA Oncology AB Says Postpones Publication Of Interim Report Q4 2024
Brief: Chosa Oncology Carried Out Directed Issue Of Sek 1,55 Mln To Further Increase Business Development Activities
Brief: Chosa Oncology Announces Decision To Postpone Release Of Interim Report For Q2 2023
Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin